EOM Pharmaceutical Holdings Announces Topline Results of its COVID-19 Clinical Trial of EOM613 in Brazil
Retrieved on:
Wednesday, September 6, 2023
Biochemistry, Diabetes, Interleukin, Serum, SC, CASA, COVID-19, Aes, Clinical trial, EOM, IL-6, Brazilian Medical Association, Research, Biomarker, Doctor of Philosophy, Rheumatoid arthritis, Hypertension, Hospital, Cytokine, AIDS, MD, Patient, System, BID, Cachexia, Blood, OTC, ICU, Principal, Safety, Pharmaceutical industry, Vaccine, IL2RA
MONTVALE, N.J., Sept. 6, 2023 /PRNewswire/ -- EOM Pharmaceutical Holdings, Inc (OTC: IMUC) ("EOM") today announced the results of its completed clinical trial in hospitalized COVID-19 patients with severe symptoms treated with its investigational immune-regulating drug product EOM613. The trial was conducted in Brazil.
Key Points:
- MONTVALE, N.J., Sept. 6, 2023 /PRNewswire/ -- EOM Pharmaceutical Holdings, Inc (OTC: IMUC) ("EOM") today announced the results of its completed clinical trial in hospitalized COVID-19 patients with severe symptoms treated with its investigational immune-regulating drug product EOM613.
- The trial was originally designed to enroll a total of 40 patients – 20 in each cohort.
- The study's topline results indicate that:
EOM613, administered by subcutaneous (SC) injection was well-tolerated by hospitalized COVID-19 patients. - This provides an additional support for EOM's future clinical drug development in various chronic inflammatory diseases," added Irach B. Taraporewala, PhD, CEO of EOM Pharmaceuticals.